QR Pharma to Present at the 44th Winter Conference on Brain Research
RADNOR, Pa.--(BUSINESS WIRE)--Jan 19, 2011 - QR Pharma, Inc., a developer of novel compounds to treat Alzheimer's disease (AD), announced today that the company will be presenting a poster on the mechanism of action and clinical data of its lead compound Posiphen® and that Dr. Maria L. Maccecchini, CEO of QR, will be a symposium speaker at the 44th Winter Conference on Brain Research, January 22-27, 2011 in Keystone, Colorado.
Poster: Mechanism of Action of Posiphen® and
Metabolites in CSF and Plasma of Mildly Cognitively Impaired
Authors: V. John, H. W. Holloway, N. Greig, C. Pan, M. Murphy, MY Chang, M.L. Maccecchini
Date: Wednesday, January 26, 2011
Time: 10:00AM to 10:00PM
Symposium: Targeting Amyloid Precursor Protein: a Route to
Impact Multiple Diseases
Speaker: Dr. Maria L. Maccecchini
Date: Thursday, January 27, 2011
Time: 8:30AM to 9:30AM
Posiphen® is in clinical development as an oral treatment for Alzheimer's disease (AD). It is a small orally active compound with high blood brain barrier permeability, which lowers amyloid precursor protein (APP) levels. Posiphen reduces the rate of synthesis of APP in cell cultures, normal, transgenic and trisomic mice.
APP is cleaved into a number of toxic peptides, including AÎ²42, which is cleaved from the middle while the others are cleaved from the N- and C- terminal ends. These peptides attack multiple pathways of neuronal cell life leading to synaptic loss and nerve cell death. This degeneration of the brain induces dysfunction, neuroinflammation and leads to cognitive impairment and neurodegeneration.
QR conducted a trial in patients with mild cognitive impairment (MCI) to confirm Posiphen's mechanism of action in humans and correlate it with the pharmacokinetics of the compound and its metabolites in CSF and plasma. Posiphen lowers levels of APP and tau by about 40%, approaching the levels found in healthy volunteers.
About QR Pharma, Inc. Headquartered in Radnor, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment, Alzheimer's disease (AD), Parkinson's disease (PD) and Down Syndrome (DS). QR currently has two product development programs – Posiphen for early stage AD and BNC for advanced AD. For more information on QR Pharma, please visit www.qrpharma.com.
Posted: January 2011